Stabilization of a recombinant ricin toxin A subunit vaccine through lyophilization

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 85, Issue 2, 2013, Pages 279-286

  Hassett, Kimberly J ^a   Cousins, Megan C ^a   Rabia, Lilia A ^a   Chadwick, Chrystal M ^b   O'Hara, Joanne M ^b,c   Nandi, Pradyot ^d   Brey, Robert N ^e   Mantis, Nicholas J ^b,c   Carpenter, John F ^d   Randolph, Theodore W ^a  

^a UCB 450   (United States)

^b WADSWORTH CENTER   (United States)

^c STATE UNIVERSITY OF NEW YORK   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e Soligenix Inc   (United States)

Author keywords

Adjuvant; Aggregation; Aluminum; Biodefense; Freeze drying; Lyophilization; Ricin; Stability; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; AMMONIUM ACETATE; HISTIDINE; NEUTRALIZING ANTIBODY; PLACEBO; RECOMBINANT RICIN TOXIN A SUBUNIT VACCINE; RIVAX; SUBUNIT VACCINE; TREHALOSE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; CONFERENCE PAPER; CONTROLLED STUDY; DRUG FORMULATION; DRUG STABILITY; DRUG STORAGE; FREEZE DRYING; GLASS TRANSITION TEMPERATURE; HIGH TEMPERATURE; HYPOGLYCEMIA; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MALE; MOISTURE; MOUSE; NONHUMAN; PARTICLE SIZE; TREATMENT RESPONSE; WATER CONTENT;

ADJUVANT; AGGREGATION; ALUMINUM; BIODEFENSE; FREEZE DRYING; LYOPHILIZATION; RICIN; STABILITY; VACCINE;

ADJUVANTS, IMMUNOLOGIC; ADJUVANTS, PHARMACEUTIC; ALUMINUM HYDROXIDE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODY FORMATION; BUFFERS; CHEMISTRY, PHARMACEUTICAL; DRUG STABILITY; DRUG STORAGE; EXCIPIENTS; FEMALE; FREEZE DRYING; HOT TEMPERATURE; MICE; PARTICLE SIZE; RECOMBINANT PROTEINS; RICIN; TRANSITION TEMPERATURE; TREHALOSE; VACCINES, SUBUNIT; WATER;

EID: 84885914636     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2013.03.029     Document Type: Conference Paper

References (46)

1. M.C. Manning, K. Patel, and R.T. Borchardt Stability of protein pharmaceuticals Pharmaceutical Research 6 1989 903 918
2. C. Goolcharran, M. Khossravi, and R.T. Borchardt Chemical pathways of peptide and protein degradation L. Hovgaar, S. Frokjaer, M. van de Weert, Pharmaceutical Formulation Development of Peptides and Proteins 1999 CRC Press London 70 88
3. E.Y. Chi, S. Krishnan, T.W. Randolph, and J.F. Carpenter Physical stability of proteins in aqueous solution: mechanism and driving force in nonnative protein aggregation Pharmaceutical Research 20 2003 1325 1336
4. D.T. Brandau, L.S. Jones, C.M. Wiethoff, J. Rexroad, and C.R. Middaugh Thermal stability of vaccines Journal of Pharmaceutical Sciences 92 2003 218 231
5. L.J. Peek, T.T. Martin, C.E. Nation, S.A. Pegram, and C.R. Middaugh Effects of stabilizers on the destabilization upon adsorption to aluminum salt adjuvants Journal of Pharmaceutical Sciences 96 2007 547 557
6. T. Estey, C. Vessely, T.W. Randolph, I. Henderson, L.J. Braun, R. Nayar, and J.F. Carpenter Evaluation of chemical degradation of a trivalent recombinant protein vaccine against botulinum neurotoxin by LysC peptide mapping and MALDI-TOF mass spectrometry Journal of Pharmaceutical Sciences 98 2009 2994 3012
7. D. Kristensen, and D. Chen Stabilization of vaccines: lessons learned Human Vaccines 6 2003 229 231
8. B. Rogers, K. Dennison, N. Adepoju, S. Dowd, and K. Uedoi Vaccine cold chain: Part I. Proper handling and storage of vaccine AAOHN Journal 58 2010 337 344
9. D.M. Matthias, J. Robertson, M.M. Garrison, S. Newland, and C. Nelson Freezing temperatures in the vaccine cold chain: a systematic literature review Vaccine 25 2007 3980 3986
10. V.A. Solanki, N.K. Jain, and I. Roy Stabilization of tetanus toxoid formulation containing aluminum hydroxide adjuvant against freeze-thawing International Journal of Pharmaceutics 414 2011 140 147
11. D.T. O'Hagen, and E. De Gregorio The path to a successful vaccine adjuvant - 'The long and winding road' Drug Discovery Today 14 2009 541 551
12. R. Rappuoli, C.W. Mandl, S. Black, and E. De Gregorio Vaccines for the twenty-first century society Nature Reviews Immunology 11 2011 865 872
13. J.F. Carpenter, M.J. Pikal, B.S. Chang, and T.W. Randolph Rational design of stable lyophilized protein formulations: some practical advice Pharmaceutical Research 14 1997 969 975
14. J. Ungar, P.W. Muggleton, J.A.R. Dudley, and M.I. Griffiths Preparation and properties of a freeze-dried B.C.G. vaccine of increased stability British Medical Journal 1962 1086 1089
15. D. Chen, and D. Kristensen Opportunities and challenges of developing thermostable vaccines Expert Review of Vaccines 8 2009 547 557
16. F. Greeraedts, V. Saluja, W. Veer, J. Amorij, H.W. Frijlink, J. Wilschut, and W.L.J. Hinrichs Preservation of the immunogenicity of dry-powder influenza H5N1 whole inactivated virus vaccine at elevated storage temperatures AAPS Journal 12 2010 215 222
17. M.I. Zapata, J.R. Feldkamp, G.E. Peck, J.L. White, and S.L. Hem Mechanism of freeze-thaw instability of aluminum hydroxycarbonate and magnesium hydroxide gels Journal of Pharmaceutical Sciences 73 1984 3 8
18. Y. Maa, L. Zhao, L.G. Payne, and D. Chen Stabilization of alum-adjuvanted vaccine dry powder formulations: mechanism and application Journal of Pharmaceutical Sciences 92 2003 319 332
19. A.L. Clausi, S.A. Merkley, J.F. Carpenter, and T.W. Randolph Inhibition of aggregation of aluminum hydroxide adjuvant during freezing and drying Journal of Pharmaceutical Sciences 97 2008 2049 2061
20. M.S. Salnikova, H. Davis, C. Mensch, L. Celano, and D.S. Thiriot Influence of formulation pH and suspension state on freezing-induced agglomeration of aluminum adjuvants Journal of Pharmaceutical Sciences 101 2012 1050 1062
21. G.L. Morefield, A. Sokolovska, D. Jiang, H. HogenEsch, J.P. Robinson, and S.L. Hem Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro Vaccine 23 2005 1588 1595
22. U.C. Nygaard, M. Samuelsen, A. Aase, and Lovik The capacity of particles to increase allergic sensitization is predicted by particle number and surface area, not by particle mass Toxicological Sciences 82 2004 515 524
23. D. Diminsky, N. Moav, M. Gorecki, and Y. Barenholz Physical, chemical and immunological stability of CHO-derived hepatitis B surface antigen (HBsAg) particles Vaccine 18 2000 3 17
24. A. Clausi, J. Cummiskey, S. Merkley, J.F. Carpenter, L.J. Braun, and T.W. Randolph Influence of particle size and antigen binding on effectiveness of aluminum salt adjuvants in a model lysozyme vaccine Journal of Pharmaceutical Sciences 97 2008 5252 5262
25. A. Clausi, A. Morin, J.F. Carpenter, and T.W. Randolph Influence of protein conformation and adjuvant aggregation on the effectiveness of aluminum hydroxide adjuvant in a model alkaline phosphatase vaccine Journal of Pharmaceutical Sciences 98 2009 114 121
26. C.J. Marsden, D.C. Smith, L.M. Roberts, and J.M. Lord Ricin: current understanding and prospects for an antiricin vaccine Expert Review of Vaccines 4 2005 229 237
27. S. Olsnes The history of ricin, abrin and related toxins Toxicon 44 2004 361 370
28. J.M. O'Hara, A. Yermakova, and N.J. Mantis Immunity to ricin: fundamental insights into toxin-antibody interactions Current Topics in Microbiology and Immunology 357 2012 209 241
29. J. Audi, M. Belson, M. Patel, J. Schier, and J. Osterloh Ricin poisoning: a comprehensive review Journal of the American Medical Association 294 2005 2342 2350
30. J.E. Smallshaw, and E.S. Vitetta Ricin vaccine development Current Topics in Microbiology and Immunology 357 2012 259 272
31. J.E. Smallshaw, J.A. Richardson, S. Pincus, J. Schindler, and E.S. Vitetta Preclinical toxicity and efficacy testing of RiVax, a recombinant protein vaccine against ricin Vaccine 23 2005 4775 4784
32. J.E. Smallshaw, J.A. Richardson, and E.S. Vitetta RiVax, a recombinant ricin subunit vaccine, protects mice against ricin delivered by gavage or aerosol Vaccine 25 2007 7459 7469
33. J.E. Smallshaw, and E.S. Vitetta A lyophilized formulation of RiVax, a recombinant ricin subunit vaccine, retains immunogenicity Vaccine 28 2010 2428 2435
34. M.A. Olson, J.H. Carra, V. Roxas-Duncan, R.W. Wannemacher, L.A. Smith, and C.B. Millard Finding a new vaccine in the ricin protein fold Protein Engineering, Design & Selection 17 2004 391 397
35. L.J. Peek, R.N. Brey, and C.R. Middaugh A rapid, three-step process for the preformulation of a recombinant ricin toxin A-chain vaccine Journal of Pharmaceutical Sciences 96 2007 44 60
36. B.S. Barrett Formulation and Development of Recombinant Protein Vaccines [Dissertation] 2009 University of Kansas Lawrence
37. S. Vecchi, S. Bufali, D.A.G. Skibinski, D.T. O'Hagan, and M. Singh Aluminum adjuvant dose guidelines in vaccine formulation for preclinical evaluations Journal of Pharmaceutical Sciences 2011 1 4
38. F. Franks Freeze-Drying of Pharmaceuticals and Biopharmaceuticals 2007 RSC Publishing Cambridge
39. E.W. Flick Industrial Solvents Handbook fifth ed. 1998 Noyes Data Corporation Westwood
40. G. Wypych Handbook of Fillers third ed. 2010 ChemTec Publishing Toronto
41. C.T. Johnston, S. Wang, and S.L. Hem Measuring the surface area of aluminum hydroxide adjuvant Journal of Pharmaceutical Sciences 91 2002 1702 1706
42. M.J. Pikal, and S. Shah Moisture transfer from stopper to product and resulting stability Developments in Biological Standardization 74 1992 165 177
43. S. Ohtake, and Y.J. Wang Trehalose: current use and future applications Journal of Pharmaceutical Sciences 100 2011 2020 2053
44. J.H. Eldridge, J.K. Staas, J.A. Meulbroek, T.R. Tice, and R.M. Gilley Biodegradable and biocompatible poly(dl-lactide-co-glycolide) microspheres as an adjuvant for Staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies Infection and Immunity 59 1991 2978 2986
45. S.H. Pincus, C.L. Cooke, and M. Maddaloni Identification of hypoglycemia in mice as a surrogate marker of ricin toxicosis Comparative Medicine 52 2002 530 533
46. Complete List of Vaccines Licensed for Immunization and Distribution in the US [Internet]. U.S. Food and Drug Administration. < http://www.fda.gov/ BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm > (updated 11.07.12; cited 19.09.12).